RPAP1 Activators
RPAP1 Activators are a collection of chemical compounds that facilitate the enhancement of RPAP1's functionality, specifically in its role as a chaperone and component of the protein quality control system within the cell. Compounds such as Forskolin, by raising cAMP levels and activating PKA, indirectly necessitate an increase in RPAP1 activity to manage the folding of PKA's substrate proteins. Proteasome inhibitors like MG132 and ALLN also contribute to RPAP1 activation by causing an accumulation of misfolded proteins that require RPAP1-mediated refolding or degradation. Inhibitors of molecular chaperones, such as Geldanamycin and 17-AAG, disrupt the function of Hsp90, thereby increasing the reliance on RPAP1 to maintain protein homeostasis. Additionally, U0126 and SB203580, which inhibit MEK and p38 MAPK respectively, can alter cellular signaling in a way that demands greater RPAP1 activity for stabilizing proteins within these pathways.
Thapsigargin and Tunicamycin induce ER stress by disrupting calcium homeostasis and N-linked glycosylation, respectively, leading to a heightened engagement of RPAP1 in the unfolded protein response. Similarly, Brefeldin A's interference with ER-Golgi transport can trigger a compensatory increase in RPAP1 activity to ensure proper protein trafficking and folding. Salubrinal's inhibition of eIF2α dephosphorylation slows translation initiation, stressing the protein folding machinery and potentially enhancing RPAP1's role in managing this stress. Finally, Lithium Chloride's inhibition of GSK-3 may modify Wnt signaling, implicating an indirect upsurge in RPAP1 activity to aid in the folding and stabilization of proteins influenced by these altered pathways. Collectively, these chemical compounds, through their specific actions on various cellular processes, ensure the robust activation of RPAP1, enabling it to effectively execute its critical function in maintaining protein homeostasis within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, which increases cAMP levels, leading to the activation of PKA. PKA can phosphorylate a variety of substrates that may indirectly enhance the chaperoning activity of RPAP1 by promoting proper folding and stabilization of client proteins. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, which may indirectly increase the demand for RPAP1 activity in refolding or degrading these proteins to maintain cellular homeostasis. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90, inhibiting its function, which may lead to an increased requirement for RPAP1 activity to compensate for the loss of Hsp90 in chaperoning client proteins. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that can affect MAPK/ERK signaling. Altered signaling dynamics may require enhanced RPAP1 activity to assist in folding or stabilizing proteins that respond to these signaling changes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could lead to a signaling imbalance that necessitates increased RPAP1 activity to manage the folding of proteins involved in the altered signaling pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by blocking the ER calcium ATPase, which may increase the workload for RPAP1 in managing the unfolded protein response (UPR) due to ER stress. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, inducing ER stress and the UPR, potentially enhancing the demand for RPAP1 function in dealing with misfolded glycoproteins. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts ER to Golgi transport, leading to ER stress and potentially increasing RPAP1 activity as part of the cellular response to maintain protein trafficking and folding. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $33.00 $102.00 | 87 | |
Salubrinal selectively inhibits dephosphorylation of eIF2α, leading to a reduced rate of translation initiation and an increased need for RPAP1 activity to manage the folding of newly synthesized proteins during ER stress. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG is an Hsp90 inhibitor similar to Geldanamycin, potentially requiring enhanced RPAP1 activity to handle client proteins that are destabilized when Hsp90 function is compromised. | ||||||